Please login to the form below

Not currently logged in
Email:
Password:

aflibercept

This page shows the latest aflibercept news and features for those working in and with pharma, biotech and healthcare.

Regeneron and Bayer drop AMD combination

Regeneron and Bayer drop AMD combination

Eylea (aflibercept) – which is partnered with Bayer – is the market leader in AMD with sales of $2.73bn in the first nine months of the year, but is facing the threat ... The studies assessed two different doses of nesvacumab in combination with

Latest news

More from news
Approximately 20 fully matching, plus 66 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2016 Deal Watch October 2016

    330. Ocular Therapeutics (US). Regeneron (US). Licence collaboration. Hydrogel sustained release aflibercept (Eylea) for wet macular degeneration.

  • Deal Watch March 2016 Deal Watch March 2016

    Collaboration &licence. $134. Regeneron/ Bayer. Ophthalmology combination therapy: nesvacumab (Ang2 antibody) and aflibercept (VEGF trap).

  • Interview: Beate Wieseler, IQWIG Interview: Beate Wieseler, IQWIG

    In addition fellow German firm Bayer criticised IQWiG's assessment of trial designs after the HTA body deemed data for eye drug Eylea (aflibercept) unsuitable in order to judge its

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

We are industry-leading thinkers when it comes to education. We use the latest academic thinking on the psychology of behaviour...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics